Clinical trial
Fluarix Immunogenicity and Safety Trial
NCT00100399 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00100399 |
|---|---|
| Title | Fluarix Immunogenicity and Safety Trial |
| Official title | A Randomized, Double-blinded, Placebo Controlled Phase III Study to Evaluate the Immunogenicity and Safety of GSK Bio Influenza Vaccine (Fluarix) Administered Intramuscularly in Healthy Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Fluarix |
| Enrollment | 1,050 |
| Start date | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Dec 31, 2004 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: